← Eichor
Study identifier: NCT06843551 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

Condition: Metastatic Pancreatic Ductal Adenocarcinoma · Metastatic Pancreatic Cancer  ·  Sponsor: Benjamin Spieler

PhasePhase 2
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to assess if radiation therapy (which uses high-energy radiation to damage or destroy cancer cells) combined with immune checkpoint inhibitors (medications that helps the body recognize and attack cancer cells) will be beneficial for patients with metastatic pancreatic ductal adenocarcinoma.

This description comes directly from the study's public registry record.

Talk to the study team

Benjamin Spieler, MD  ·  305-243-4229  ·  bxs737@med.miami.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of MiamiMiami, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06843551